1620097-06-4

Usage

Uses

Used in Pharmaceutical Industry:
Suvorexant intermediate is used as a key chemical intermediate for the synthesis of Suvorexant, a medication for treating insomnia. It is crucial in the formation of the drug's molecular structure and biological activity, contributing to its effectiveness as an orexin receptor antagonist.
Used in Insomnia Treatment:
Suvorexant intermediate is used as a precursor in the production of Suvorexant, which is an orexin receptor antagonist. This medication is specifically designed to target the orexin system in the brain, which plays a role in regulating wakefulness. By blocking these receptors, Suvorexant helps to promote sleep and is used for the treatment of insomnia.

Upstream product

• 150651-57-3 1-Benzyl-2,3,6,7-tetrahydro-5-methyl-1H-1,4-diazepine 
• 100-52-7 benzaldehyde 
• 174799-52-1 tert-butyl {2-[benzylamino]ethyl}carbamate 
• 17136-36-6 N-benzylglycine 
• 53386-64-4 methyl 2-(benzylamino)acetate 
• 150651-53-9 4-butan-2-one 
• 150651-47-1 N-(2-azidoethyl)-N-benzylamine 

Downstream Products

• 1030377-32-2 1-(7(R)-methyl-1,4-diazepan-1-yl)-1-[5-methyl-2-(2H-1,2,3-triazole-2-yl)phenyl]methanone 
• 1030377-33-3 Suvorexant 
• 1620097-07-5 (R)-(4-benzyl-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone 
• 1638743-92-6 tert-butyl (R)-7-methyl-1,4-diazepane-1-carboxylate 

Relevant academic research and scientific papers

Biocatalytic Access to 1,4-Diazepanes via Imine Reductase-Catalyzed Intramolecular Asymmetric Reductive Amination

An enzymatic intramolecular asymmetric reductive amination has been developed for the synthesis of chiral 1,4-diazepanes. Several enantiocomplementary IREDs were identified for the synthesis of (R)-and (S)-5-chloro-2-(5-methyl-1,4-diazepan-1-yl)benzo[d]ox

Synthesis and biological activity evaluation of azacycloheptane sulfonamide derivatives as potential orexin receptor antagonists

As the orexin signaling system is crucial for the regulation of the sleep/wake cycle, inhibitors of orexin-1 and orexin-2 receptors are of significant interest in the treatment of insomnia. Herein, a series of novel azacycloheptane sulfonamide derivatives were designed and synthesized, and all the compounds were evaluated as potential orexin receptor inhibitors by FLIPR Tetra calcium assay. A majority of the tested azacycloheptane sulfonamide derivatives showed OX1R and OX2R inhibitory activity. Chloro-substituted derivatives functionalized at the C5 or C6 position of the benzoxazole group exhibited better inhibitory activity for OX1R and OX2R than unsubstituted derivatives functionalized at C5 or C6. In addition, phenyl group modification had positive effects on the inhibitory activities, and an electron-withdrawing fluorine group at the ortho or meta position of the phenyl ring improved the OX2R inhibitory activity of the derivatives. This suggests that azacycloheptane sulfonamide derivatives are promising scaffolds for the development of OX1R and OX2R antagonists.

PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT

A novel processes for the preparation of suvorexant (formula I), its related compounds and its intermediates that are simple, economical and commercially viable. (I)

Used for preparing suvorexant compound and method for preparing same

The invention relates to three novel compound formulas I, II and III for preparing suvorexant, stereoisomers or salt thereof and a preparation method of the formulas I, II and III. The invention also relates to a method for preparing the suvorexant. The preparation method disclosed by the invention can be used for synthesizing to obtain the chiral compounds I, II and III through a chiral initiator and use the chiral compounds I, II and III for the synthesis of the suvorexant and has the advantages of easiness for operation, moderation in reaction condition, easiness for post processing, easiness for purification, high yield, high ee value and easiness for industrialization.

Facile synthesis of suvorexant, an orexin receptor antagonist, via a chiral diazepane intermediate

A facile synthesis of suvorexant, an orexin receptor antagonist, is described. The key intermediate 6 was prepared from R-3-aminobutyric acid through protection, condensation, deprotection, cyclization, and hydrogenation steps. The title product was obtained with a total yield of 31% (>99% ee) after eight linear steps using commercially available raw materials.

Synthesis of 2,3,6,7-Tetrahydro- and 2,3,4,5,6,7-Hexahydro-1H-1,4-diazepines via a Tandem Michael-type Addition-Intramolecular Aza-Wittig Sequence

Intramolecular aza-Wittig reaction of azides derived from 1,2-amino azides and α,β-unsaturated ketones leads to 2,3,6,7-tetrahydro-1H-1,4-diazepines.Reduction of these compounds with lithium aluminium hydride affords the corresponding saturated heterocycles.